S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
Log in
NASDAQ:CODX

Co-Diagnostics Stock Forecast, Price & News

$10.97
-0.09 (-0.81 %)
(As of 12/2/2020 05:08 PM ET)
Add
Compare
Today's Range
$10.62
Now: $10.97
$11.30
50-Day Range
$10.49
MA: $13.08
$15.19
52-Week Range
$0.88
Now: $10.97
$30.99
Volume1.10 million shs
Average Volume6.58 million shs
Market Capitalization$310.11 million
P/E Ratio13.54
Dividend YieldN/A
Beta-2.91
Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.
Co-Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 3.1 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CODX
CUSIPN/A
Phone801-438-1036
Employees25

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$220,000.00
Book Value$1.87 per share

Profitability

Net Income$-6,200,000.00

Miscellaneous

Market Cap$310.11 million
Next Earnings Date3/30/2021 (Estimated)
OptionableNot Optionable
$10.97
-0.09 (-0.81 %)
(As of 12/2/2020 05:08 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CODX News and Ratings via Email

Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions

How has Co-Diagnostics' stock price been impacted by COVID-19?

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CODX stock has decreased by 16.4% and is now trading at $11.03.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Co-Diagnostics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Co-Diagnostics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Co-Diagnostics?

Wall Street analysts have given Co-Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Co-Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Co-Diagnostics' next earnings date?

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, March 30th 2021.
View our earnings forecast for Co-Diagnostics
.

How were Co-Diagnostics' earnings last quarter?

Co-Diagnostics, Inc. (NASDAQ:CODX) announced its earnings results on Sunday, November, 15th. The company reported $0.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.63 by $0.10. Co-Diagnostics had a return on equity of 93.48% and a net margin of 53.81%.
View Co-Diagnostics' earnings history
.

What price target have analysts set for CODX?

2 brokers have issued 12-month target prices for Co-Diagnostics' shares. Their forecasts range from $20.00 to $29.00. On average, they anticipate Co-Diagnostics' stock price to reach $24.50 in the next twelve months. This suggests a possible upside of 122.1% from the stock's current price.
View analysts' price targets for Co-Diagnostics
.

Who are some of Co-Diagnostics' key competitors?

What other stocks do shareholders of Co-Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ).

Who are Co-Diagnostics' key executives?

Co-Diagnostics' management team includes the following people:
  • Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 67, Pay $295k)
  • Dr. Brent C. Satterfield, Co-Founder & Chief Science Officer (Age 43, Pay $237.5k)
  • Mr. Reed L. Benson, CFO & Sec. (Age 72, Pay $215k)
  • Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic Alliances
  • Mr. Cameron Gundry, Head of Commercialization LATAM/EUR

When did Co-Diagnostics IPO?

(CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

What is Co-Diagnostics' stock symbol?

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Who are Co-Diagnostics' major shareholders?

Co-Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (1.63%), Morgan Stanley (0.64%), Wells Fargo & Company MN (0.57%), IFG Advisory LLC (0.51%), Commonwealth Equity Services LLC (0.31%) and AQR Capital Management LLC (0.30%). Company insiders that own Co-Diagnostics stock include Dwight H Egan, Eugene Durenard, Reed L Benson and Richard S Serbin.
View institutional ownership trends for Co-Diagnostics
.

Which major investors are selling Co-Diagnostics stock?

CODX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Paloma Partners Management Co, Strategic Wealth Management Group LLC, and Charles Schwab Investment Management Inc.. Company insiders that have sold Co-Diagnostics company stock in the last year include Dwight H Egan, Eugene Durenard, Reed L Benson, and Richard S Serbin.
View insider buying and selling activity for Co-Diagnostics
.

Which major investors are buying Co-Diagnostics stock?

CODX stock was acquired by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, AQR Capital Management LLC, IFG Advisory LLC, Commonwealth Equity Services LLC, BNP Paribas Arbitrage SA, Massachusetts Financial Services Co. MA, Bank Julius Baer & Co. Ltd Zurich, and Natixis.
View insider buying and selling activity for Co-Diagnostics
.

How do I buy shares of Co-Diagnostics?

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Co-Diagnostics' stock price today?

One share of CODX stock can currently be purchased for approximately $11.03.

How big of a company is Co-Diagnostics?

Co-Diagnostics has a market capitalization of $311.81 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Co-Diagnostics employs 25 workers across the globe.

What is Co-Diagnostics' official website?

The official website for Co-Diagnostics is www.codiagnostics.com.

How can I contact Co-Diagnostics?

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at 801-438-1036 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.